Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053963 · ClinicalTrials.gov registry record · Phase 1
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00053963: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00053963 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053963, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
Interventions
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053963
The ClinicalTrials.gov registry entry for NCT00053963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which romidepsin is the first listed.
NCT00053963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053963 about?
NCT00053963 is a clinical study titled "FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia". This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
What is the current status of trial NCT00053963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00053963?
The interventions under investigation include: romidepsin (DRUG).
Who is sponsoring clinical trial NCT00053963?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.